Morgan Stanley Aytu Biopharma, Inc Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.15 - $4.0 $0 - $24	6 Added 0.03%	20,491 $3,000
Q3 2022 Nov 14, 2022	SELL	$0.19 - $3.8 $950 - $19,003	-5,001 Reduced 19.62%	20,485 $4,000
Q2 2022 Oct 27, 2022	SELL	$0.46 - $1.08 $11,836 - $27,790	-25,732 Reduced 50.24%	25,486 $17,000
Q2 2022 Aug 15, 2022	SELL	$0.46 - $1.08 $11,836 - $27,790	-25,732 Reduced 50.24%	25,486 $17,000
Q1 2022 Oct 27, 2022	BUY	$1.08 - $1.55 $27,790 - $39,884	25,732 Added 100.97%	51,218 $56,000
Q1 2022 May 13, 2022	SELL	$1.08 - $1.55 $150,037 - $215,332	-138,924 Reduced 73.06%	51,218 $56,000
Q4 2021 Feb 14, 2022	SELL	$1.35 - $2.95 $253,503 - $553,951	-187,780 Reduced 49.69%	190,142 $257,000
Q3 2021 Nov 15, 2021	BUY	$2.78 - $5.12 $1.05 Million - $1.93 Million	377,922 New	377,922 $1.09 Million

Ticker AYTU
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 62,432,700
Market Cap $88.7M
Description
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT f...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.